Top Markets
Coin of the day
Purple Biotech Ltd. Purple Biotech Ltd.

Purple Biotech Ltd.

PPBT
Classement en actions #40641
Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies... Purple Biotech Ltd., a clinical-stage company, is focused on creating therapies for cancer patients in the United States, specifically addressing challenges like tumor immune evasion and drug resistance. Its diverse oncology pipeline includes CM24, a humanized monoclonal antibody that targets and blocks carcinoembryonic antigen related cell adhesion molecule 1 (CEACAM1). Currently in Phase 2 clinical trials, CM24 is being investigated as a combination therapy with anti-PD-1 checkpoint inhibitors for treating pancreatic ductal adenocarcinoma. Another candidate is NT219, a small molecule compound in Phase 1/2 clinical trials, which functions by inhibiting insulin receptor substrate 1 and 2 (IRS1/2) and signal transducer and activator of transcription (STAT). This compound is being developed for recurrent and/or metastatic squamous cell carcinoma of the head and neck, or colorectal adenocarcinoma. Furthermore, IM1240, a multi-valent antibody designed to activate an anti-tumoral immune response against 5T4-positive tumors, is in its preclinical stage. The company has established significant collaborations, including an agreement with Bristol Myers Squibb Company for Phase 2 clinical trials to assess CM24 in combination with the PD-1 inhibitor nivolumab and chemotherapy, as well as a partnership with Mor Research Applications. Formerly known as Kitov Pharma Ltd., the company adopted the name Purple Biotech Ltd. in December 2020 and is headquartered in Rehovot, Israel.
Prix de l'action
$0.00323826
Dernière synchronisation: 2026-08-12
Capitalisation boursière
$104.81K
Changement (1 jour)
0.00%
Changement (1 an)
-70.42%
Pays
IL
Échange Purple Biotech Ltd. (PPBT)

Catégorie

Ratio P/S pour Purple Biotech Ltd. (PPBT)
Ratio P/S au 2026 TTM : 0
Selon les derniers rapports financiers et le cours de l'action de Purple Biotech Ltd., le ratio cours/ventes actuel (TTM) est 0. À la fin de 2026, le ratio P/S était de 0.
Historique du ratio P/S pour Purple Biotech Ltd. de 2026 à 2026
Ratio P/S à la fin de chaque année
Année Ratio P/S Changez
Pas assez de données pour les dates fournies.
Ratio P/S pour des entreprises similaires ou concurrentes
Entreprise Ratio P/S Différence de Ratio P/S Pays
9.88 -
US
10.30 -
NL
- -
CH
- -
KR
4.98 -
BE